Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study

Tőkés, Tímea and Szentmártoni, Gyöngyvér and Torgyík, László and Kajáry, Kornélia and Lengyel, Zsolt and Györke, Tamás and Molnár, Béla Á. and Tőkés, Anna-Mária and Kulka, Janina and Dank, Magdolna (2015) Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study. Croatian Medical Journal, 56 (2). pp. 128-138. ISSN 0353-9504

Preview

Text TőkésTímea-CroatMedJ.pdf Download (233kB) | Preview

Abstract

Aim To evaluate (I) trastuzumab-containing primary systemic therapy (PST) in human epidermal growth factor receptor 2 (Her2) overexpressing breast carcinomas.; (II) compare the pa - tients who achieved and those who did not achieve pathologi - cal complete remission (pCR), and (III) analyze the accuracy of different clinical-imaging modalities in tumor response moni - toring. Methods 188 patients who received PST between 2008 and 2014 were reviewed and 43 Her2 overexpressing breast can - cer patients (28 Luminal B/Her2-positive and 15 Her2-positive) were enrolled. 26 patients received mostly taxane-based PST without trastuzumab (Group 1) and 17 patients received tras - tuzumab-containing PST (Group 2). We compared the con - cordance between pCR and complete remission (CR) defined by breast-ultrasound, CR defined by standard 18F-fluoro-de - oxy-glucose positron emission tomography and computer - ized tomography (FDG-PET/CT) criteria (Method 1) and CR defined by a novel, breast cancer specific FDG-PET/CT criteria (Method 2). Sensitivity (sens), specificity (spec), and positive (PPV ) and negative predictive values (NPV ) were calculated. Results Ten patients (38.5%) in Group 1 and eight (47%) in Group 2 achieved pCR. pCR was significantly more frequent in Her2-positive than in Luminal B/Her2-positive tumors in both Group 1: ( P = 0.043) and Group 2: ( P = 0.029). PET/CT evaluated by the breast cancer specific criteria (Method 2) differentiated pCR from non-pCR more accurately in both groups (Group 1: sens = 77.8%, spec = 100%, PPV = 100%, NPV = 71.4%; Group 2: sens = 87.5%, spec = 62.5%, PPV = 70%, NPV = 83.3%) than standard PET/CT criteria (Method 1) (Group 1: sens = 22.2% spec = 100% PPV = 100% NPV = 41.7%; in Group 2: sens = 37.5%, spec = 87.5%, PPV = 75% NPV = 58.3%) or breast ultrasound (Group 1, sens = 83.3% spec = 25% PPV = 62.5% NPV = 50%; Group 2, sens = 100% spec = 12.5% PPV = 41.6% NPV = 100%). Conclusion The benefit of targeted treatment with trastu - zumab-containing PST in Her2 overexpressing breast cancer was defined in terms of pCR rate. Luminal B/Her2-positive subtype needs further subdivision to identify patients who would benefit from PST. Combined evaluation of tumor re - sponse by our novel, breast cancer specific FDG-PET/CT crite - ria accurately differentiated pCR from non-pCR patients.

Actions (login required)

Edit Item